Part of the inflammatory response in Alzheimer's disease (AD) is the upregulation of the inducible nitric oxide synthase (NOS2) resulting in increased NO production. NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid b (Ab) as an NO target, which is nitrated at tyrosine 10 (3NTyr 10 -Ab). Nitration of Ab accelerated its aggregation and was detected in the core of Ab plaques of APP/PS1 mice and AD brains. NOS2 deficiency or oral treatment with the NOS2 inhibitor L-NIL strongly decreased 3NTyr 10 -Ab, overall Ab deposition and cognitive dysfunction in APP/PS1 mice. Further, injection of 3NTyr 10 -Ab into the brain of young APP/PS1 mice induced b-amyloidosis. This suggests a disease modifying role for NOS2 in AD and therefore represents a potential therapeutic target.
INTRODUCTION
Alzheimer's disease (AD) is clinically characterized by progressive memory loss and decline of cognitive functions. Besides the classical histopathological hallmarks, extracellular amyloid b (Ab) deposition and neurofibrillary tangles of tau protein, neuroinflammation has been established as a major component (Querfurth and LaFerla, 2010) . This inflammatory response includes the activation of astrocytes and microglial cells localized to senile plaques and the release of biochemical markers, including cytokines, chemokines, and nitric oxide, that are found to be increased in the brains of patients with AD (Glass et al., 2010) . While the generation of Ab peptides from the amyloid precursor protein as well as their propensity to aggregate into b-cross sheet fibrils has been well characterized (Querfurth and LaFerla, 2010) , the mutual interactions between neuroinflammation, Ab formation and deposition remain to be elucidated.
While neuronal nitric oxide synthase 1 (NOS1) is constitutively expressed in a subset of neurons, AD-associated inflammation can increase NOS1 and the inducible nitric oxide synthase (NOS2) expression in neurons Vodovotz et al., 1996; Heneka et al., 2001 ) along with the upregulation of NOS2 in microglia and astrocytes Vodovotz et al., 1996; Heneka et al., 2001) . NOS2 catalyzes the generation of NO, which has been implicated in impairment of mitochondrial respiration (Beal, 2000) , synaptic failure, and neuronal cell death (Nakamura and Lipton, 2009) during neurodegeneration. One of the fingerprints of NO is tyrosine nitration, a posttranslational protein modification, resulting in the formation of 3 0 -nitrotyrosine residues (Radi, 2004 ) that can induce structural changes leading to protein aggregation (Radi, 2004) . Indeed, AD lesions reveal the pathological pattern of nitrosative injury Castegna et al., 2003; Colton et al., 2008; Lü th et al., 2002) , prominently in brain areas that are affected in AD (Hensley et al., 1998) .
So far, it is unknown why the Ab peptide, present at high levels under nonpathological conditions in humans, under certain circumstances starts to multimerize leading to the formation of Ab oligomers and further to high molecular weight fibrils and plaques. In murine models of AD, the overexpression of the human amyloid precursor protein (APP) results in the formation of plaque pathology, whereas wild-type mice and rats do not innately develop amyloid deposits with age (Shivers et al., 1988) , even after overexpression of endogenous APP (Jankowsky et al., 2007) .
APP is a highly conserved transmembrane protein with only 4% difference in amino acid between human, monkey, mouse, and rat sequence. Three of these differences (R5 / G, Y10 / F, and H13 / R) are localized to the Ab domain ( Figure 1A ), giving rise to speculations about the importance of these changes for amyloid deposition. Surprisingly, synthetic peptides containing these mutations do not differ in the propensity to form high molecular weight aggregates in vitro (Wahle et al., 2006 ). An alternative explanation could be that posttranslational modifications of the Ab peptide are essential to initiate its aggregation, as it has been shown for pyroglutamate-modified Ab (Querfurth and LaFerla, 2010; He and Barrow, 1999) . Of note, induction of aggregation by NO modifications has been reported for other disease-relevant proteins (Nakamura and Lipton, 2009) . With regards to the amino acid sequence of Ab, the tyrosine at position 10 is a potential target for protein nitration.
Since there is so far no mechanistic explanation of how expression of NOS2 and the subsequent production of NO and its reaction products modulate the progression of AD, we speculated that nitration of Ab might contribute to AD pathology.
We report here the presence of Ab nitrated at tyrosine 10 in AD as well as in AD mouse models. This modification accelerated the deposition of human Ab. We further find that Ab burden and deficits in memory formation were ameliorated in APP/PS1 NOS2 (À/À) mice or by pharmacological treatment with a NOS2 inhibitor. Finally, nitrated Ab was able to induce b-amyloidosis in APP/PS1 mice. These results underline the importance of this posttranslational modification as a potential therapeutic target.
RESULTS

Detection of Nitrated Ab in AD Tissue
Since tyrosine 10 represents a potential nitration side (Figure 1A) , we tested the availability of this amino acid for this posttranslational modification in vitro. Performing mass spectrometry analysis after tryptic digestion of Ab 1-42 that was either nitrated using peroxynitrite or the NO-donor Sin-1, we observed the described fragmentation pattern of a nitrated peptide (Petersson et al., 2001 ). This pattern was missing using Ab 1-42 bearing a tyrosine to alanine mutation (see Figure S1 available online), suggesting that tyrosine 10 is a potential nitration target in vitro.
To detect Ab nitrated at tyrosine 10 (3NTyr 10 -Ab), we generated an antiserum specifically recognizing this epitope (3NTyr 10 -Ab antiserum). This antiserum showed strong immunoreactivity against peroxynitrite-treated Ab 1-42 peptide or synthetically-nitrated Ab 1-42 (Ab42(3NT)Y), which was absent in case of the untreated peptide ( Figure 1B ). We observed a very low amount of reactivity when treating Ab 1-42 Y10F mutant peptide with peroxynitrite. This might be caused by the conversion of phenylalanine to tyrosine by hydroxyl radicals generated during the decomposition of peroxynitrite (Ferger et al., 2001 ). In accordance with this, there was no reactivity toward Ab 1-42 bearing a Y10A mutation after incubation with peroxynitrite ( Figure S1 ). Using this antiserum, we were able to detect 3NTyr 10 -Ab in the supernatant of NOS2 overexpressing HEK293 cells after exogenous addition of nonaggregated Ab, demonstrating that NOS2 is able to induce this posttranslational modification before Ab deposits form ( Figure S1 ). Immunohistochemical analysis of AD and control brains by 3NTyr 10 -Ab antiserum revealed a lack of immunoreactivity in control brains, whereas in AD brain, the core of amyloid plaques was intensively labeled, as confirmed by IC16 double staining ( Figure 1C ). Measuring the relative amounts of 3NTyr 10 -Ab by sandwich ELISA in SDS-soluble fractions of human brain samples, we detected 3NTyr 10 -Ab in the SDS fraction of AD patients and only to very low amount in nondemented controls ( Figure 1D ). Further, the relative signal ratio of 3NTyr 10 -Ab between control and AD patients was comparable to that of Ab 1-42 ( Figure 1D ). Of note, we failed to detect any 3NTyr 10 -Ab in human cerebrospinal fluid (CSF) of control, mild cognitive impaired, and AD patients underlining the insoluble properties of this species ( Figure S1) . See also Figure S1 .
Nitration of Ab Is Modulated by NOS2 in APP/PS1 Mice Analysis of brain sections from 5-and 12-month-old APP/PS1 mice revealed a colocalization of antibody IC16 against Ab with the 3NTyr 10 -Ab antiserum from beginning of plaque formation starting at 5 months of age in this AD mouse model ( Figures  2A and 2B ). This costaining was observed in all brain areas where amyloid plaques are formed. In addition, colocalization was observed independently of plaque size, since it was already detectable in tiny plaques of 10 mm diameter in 5-month-old animals ( Figure 2C ), suggesting that formation of 3NTyr 10 -Ab is an early event in plaque development. Similar to human AD brain, in APP/PS1 the 3NTyr 10 -Ab immunoreactivity was localized to the core of the plaque surrounded by IC16 immunoreactivity ( Figure 2D ). Evaluation of individual Ab plaque sizes by immunohistochemistry with antibody IC16 and the area of the 3NTyr 10 -Ab positive core of 5-and 9-month-old APP/PS1 mice revealed that there are no changes in the average 3NTyr 10 -Ab core size (Figures 2E and 2F) , suggesting that the core, once formed, does not substantially increase in size any further. Nevertheless, we observed plaque growth between 5 and 9 months that was solely caused by accumulation of nonnitrated Ab, as detected by IC16 immunoreactivity (Figures 2E and 2F ). As a consequence, there was a highly significant drop in the 3NTyr 10 -Ab/Ab ratio ( Figure 2G ).
In addition, we were able to immunoprecipitate 3NTyr 10 -Ab of brain homogenates sequentially extracted with PBS, RIPA, SDS, and HIFP using 3NTyr 10 -Ab antiserum. Using 6E10 as detection antibody, we were able to detect high amounts of nitrated Ab in the SDS-soluble fraction and to smaller extent in the RIPA-and HFIP-soluble fractions of APP/PS1 mice (Figure 2H) . Determining the relative amounts of 3NTyr 10 -Ab in SDS fractions of wild-type, APP/PS1, and APP/PS-1 NOS2 (À/À) animals by sandwich ELISA, we were unable to detect this species in wild-type mice, but in APP/PS1 mice. In turn, APP/PS1 mice lacking NOS2 (À/À) showed a 74% reduction of 3NTyr 10 -Ab ( Figure 2I) . S2). In case of the nonmutated Ab 1-42 , we observed the incorporation of nitrated Ab 1-42 into oligomers ( Figure 3C ). There was a very low amount of nitrated Ab 1-42 Y10F detectable using the 3NTyr 10 -Ab antiserum. Finally, we confirmed our western blot results by detecting an increased formation rate of b sheet amyloid fibril structures of nitrated Ab 1-42 using thioflavin T ( Figure 3D ), which was prevented using the Ab42Y10F peptide treated with peroxynitrite.
Oxidative conditions can also result in the formation of dityrosine cross-linked proteins (Kato et al., 2000) . We therefore investigated whether peroxynitrite is able to induce this modification as well. Using the dityrosine specific antibody IC3 we were able to detect dityrosine crosslinked Ab in vitro after incubation with increasing concentrations of peroxynitrite ( Figure 3E ). High concentrations of peroxynitrite resulted in decreased formation of this species, whereas formation of 3NTyr 10 -Ab increased even further ( Figure 3E ).
Dityrosine immunoreactivity was also found to be present in the insoluble fractions of aggregated Ab ( Figure 3F ). In addition, we performed immunohistochemical analysis of dityrosine with Ab or 3NTyr 10 -Ab in sections of APP/PS1 mice, revealing plaque localization and 3NTyr 10 -Ab colocalization of dityrosine
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Nitration of Amyloid b in Alzheimer's Disease immunoreactivity ( Figure 3G ). These results suggest that dityrosine formation might also contribute to Ab aggregation.
NOS2 Deficiency Protects from Behavioral Phenotype and Reduces Ab Load in APP/PS1 Mice
Looking at effects on spatial memory formation by radial arm maze in 12-month-old APP/PS1 mice, we noticed a strong protection of the NOS2 gene knockout for memory deficits (Figure 4A ). In addition, we conducted a therapeutic approach by treating plaque containing mice from 7-12 months with the selective NOS2 inhibitor L-NIL resulting in a reversion of APP/ PS1 phenotype concerning reference memory errors ( Figure 4A ). Since memory formation and synaptic plasticity are closely connected, we determined the hippocampal long-term potentiation (LTP) of the CA1 region in response to a stimulus of the Schaffer's collaterals in WT, APP/PS1, NOS2 (À/À), APP/PS1 NOS2 (À/À), and APP/PS1 L-NIL treated mice at 4 months (Figure S3) . APP/PS1 mice of that age already contain insoluble, high-density amyloid depositions that are positive 3NTyr 10 -Ab ( Figure S3 ), that were also found at later age, as well as in AD patients ( Figure S3 ). Analysis of the LTP in APP/PS1 mice showed a reduction LTP, which was not observed in wild-type, NOS2-deficient, or L-NIL-treated mice ( Figure S3 ).
In order to establish a causal link between the observed protective phenotype of NOS2 deficiency and Ab nitration, we studied the effects of nitrated Ab on synaptic plasticity. Therefore we treated wild-type (WT) mice acute hippocampal slices with either untreated Ab 1-42 , nitrated Ab 1-42 , or a control sample that underwent the same nitration steps without adding Ab. The application of untreated Ab 1-42 decreased LTP 55-60 min after TBS application compared to the slices treated with the control sample (p = 0.03, Student's t test); Figure 4B ). When Ab 1-42 was additionally nitrated, the initial phase of LTP was already significantly decreased compared to controls and this resulted in highly significant differences 55-60 min after TBS (p = 0.0001, Student's t test). The average potentiation in control treated slices was 199 ± 8.6% (n = 11 slices /5 animals), Ab 1-42 treated slices reached a value of 163% ± 10.9% (n = 11 slices/6 animals), and peroxynitrite treated Ab 1-42 led to a potentiation of 141% ± 7.8% (n = 12 slices/7 animals) ( Figure 4B ). Comparing the results of the nitrated Ab 1-42 with the untreated Ab 1-42 revealed that the nitrated Ab 1-42 showed a significantly reduced potentiation (t = 60 min, p = 0.02; t = 80 min, p = 0.028; Student's t test) in comparison to untreated Ab 1-42 . Overall the strongest effect on synaptic plasticity was observed, when Ab 1-42 was nitrated. This is in line with the behavioral data and supports the notion, that nitrated Ab 1-42 is more powerful in disturbing processes of synaptic plasticity than Ab 1-42 alone.
Subsequent analysis of the mice from the behavioral experiment for Ab 1-40 and Ab 1-42 revealed a strong reduction in the SDS-soluble fraction ( Figures 4C-4F) , which was smaller than the reduction of 3NTyr 10 -Ab ( Figure 2I ). Consequently, we observed an increase in the Ab40/3NTyr 10 -Ab and Ab42/ 3NTyr 10 -Ab ratio ( Figure 4G ). There were no changes in the expression of APP, neprilysin, and IDE at 12 months of age ( Figures 4C and 4D ). These findings were confirmed by reduced plaque load in the neocortex and hippocampus in APP/PS1 NOS2 (À/À) mice by thioflavin S staining (Figures 4H and 4I ). In keeping with this, loss of NOS2 activity during the phase of plaque formation has a beneficial effect on the formation of Ab deposits.
Nitrated Ab Induces Aggregation and Plaque Formation
It is conceivable that the formation of amyloid plaques needs a nucleation event. We therefore tested whether nitrated Ab 1-42 can act as a seed of deposition. Testing whether small amounts of nitrated Ab 1-42 induces the formation of Ab oligomers in vitro, we observed a concentration dependent increase in high molecular weight oligomers by western blot analysis ( Figure 5A ). To test the hypothesis in vivo, we injected 2.5 ml of a 0.5 mg/ml solution of either Ab 1-42 or nitrated Ab 1-42 aged for 18 hr into the brain of 2.5-month-old APP/PS1 mice. Verification of the injected Ab peptides by western blot demonstrated the nitration status using the 3NTyr 10 -Ab antibody and increased formation of Ab oligomers using antibody 6E10 ( Figure 5B ). Analysis of the mice after 8 weeks showed strong 3NTyr 10 -Ab immunoreactivity in case of the mice injected with nitrated Ab 1-42 ( Figure 5D ). In addition, nitrated Ab 1-42 was able to induce amyloid seeds that were localized distant from the injection side ( Figure 5D ), that were missing in mice injected with nonnitrated Ab ( Figure 5C ). These seeds were composed of nitrated Ab surrounded by nonnitrated Ab ( Figure 5E ), thus resembling the immunomorphological appearance of plaques detected in AD brains. In addition, this species also evoked an increase of Iba1 suggesting a role for microglial activation.
DISCUSSION
Direct propagation of Ab aggregation by neuroinflammation is unknown; even so, this may be important for the development of disease modifying therapies. In this study, we propose a causative link among the Ab cascade, activation of NOS2, and the subsequent increase in its reaction product nitric oxide during AD. NO is a free radical gas that functions physiologically as a diffusible neurotransmitter and signaling molecule. Depending on its concentration it can conduct different actions. At low concentrations, it competes with oxygen for cytochrome oxidase, thereby regulating energy metabolism (Poderoso, 2009) . Indirect effects are also mediated by regulating cGMP synthesis and subsequently cGMP-dependent signaling cascades (Poderoso, 2009) . However, at high concentration, NOS2-derived NO results in the formation of reactive peroxynitrite, which causes irreversible nitration or nitrosylation of specific amino acid residues, resulting in aberrant protein conformation and function, e.g., in the inhibition of mitochondrial respiration (Szabó et al., 2007) .
Previously, nitrosative stress has been demonstrated in disease relevant brain areas in AD Castegna et al., 2003; Colton et al., 2008; Lü th et al., 2002; Hensley et al., 1998) . In line with this, induction of NOS2 expression has been demonstrated in AD (Vodovotz et al., 1996; Heneka et al., 2001 ) and in the Tg2576 AD mouse model . Since nitric oxide and its reaction products like peroxynitrite are able to introduce posttranslational modifications at cysteine and tyrosine residues (Gow et al., 2004) , we Neuron Nitration of Amyloid b in Alzheimer's Disease speculated whether the tyrosine at position 10 of Ab might be a possible target for NOS2-mediated nitration, thereby influencing its amyloidogenic properties.
Indeed, we were able to demonstrate that Ab nitrated at tyrosine 10 has an increased propensity to form high molecular weight aggregates in vitro. In line with this, we observed 
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Nitration of Amyloid b in Alzheimer's Disease a protective effect on amyloid plaque formation and memory function by deleting the NOS2 gene from APP/PS1 mice. Our data are in accordance with a previous report using the Tg2576 mouse model crossbred with the human PS1 A246E mutation (Nathan et al., 2005) . In addition, we observed similar effects after oral long-term application of the NOS2-specific substrate analog inhibitor L-NIL. Besides its selectivity (23-fold over NOS1 and 49-fold over NOS3) (Moore et al., 1994; Alderton et al., 2001) , the oral bioavailability and its brain penetration have been demonstrated (Rebello et al., 2002) . Of note, the safety of L-NIL has already been demonstrated in patients suffering from asthma and in healthy controls (Hansel et al., 2003) .
Importantly, improved spatial learning and memory in NOS2 (À/À) or L-NIL-treated APP/PS1 mice may well be causally linked to the nitration of Ab 1-42 as the latter decreased hippocampal long-term potentiation more effectively when compared to nonnitrated Ab 1-42 , suggesting that nitration of Ab may exert a direct effect on synaptic transmission even before its deposition in plaques. This is additionally supported by the observation that deletion of NOS2 or L-NIL treatment in young APP/PS1 mice results in improved LTP. Nevertheless, additional NO-mediated effects, likely to be independent of nitrated Ab, that protect from Ab-induced suppression of LTP have been reported (Wang et al., 2004) . Further, the reduction of Ab in APP/PS1 
Nitration of Amyloid b in Alzheimer's Disease NOS2 (À/À) mice may lower the production of proinflammatory cytokines by activated microglia and astrocytes and thereby protect from LTP suppression (Hauss-Wegrzyniak et al., 2002; Griffin et al., 2006; Tancredi et al., 1992 Tancredi et al., , 2000 . In contrast, a beneficial role of NOS2 in an AD mouse model expressing the APP Swedish mutation has been suggested. Deletion of NOS2 resulted in increased Ab deposition and improved spatial memory Colton et al., 2006 Colton et al., , 2008 . Even so there has been no mechanistic explanation for the changes in Ab burden in this study, a main difference to our study is the usage of an AD mouse model lacking a PS1 transgene, which may account for the opposite effects observed in this study and in a previous one (Nathan et al., 2005) . Colton et al. argued that the enhanced upregulation of NOS2 is an overexpression artifact of the PS1 transgene caused by an inflammatory response within resident immune cells, as evidenced in vitro by Lee et al. (2002) . However, such an effect has not been observed in rodent AD models or in patients with sporadic AD. Nevertheless, an impact of the PS1 DExon 9 transgene on immune cells, like microglia cells, is unlikely, since the prion promoter driven APP/PS1 mouse model system used in this study results in the expression of both transgenes (APPsw and PS1 DExon 9) almost exclusively confined to neurons (Kretzschmar et al., 1986) .
Based on the evidence presented in this study, we propose that the observed decrease in amyloid burden in NOS2 knockout or L-NIL-treated APP/PS1 mice is attributed to a new NOinduced posttranslational Ab modification that critically increases its aggregation and solubility profile. This is supported by the observation that nitrated Ab is localized to SDS-soluble fractions in APP/PS1 mice. In addition, nitrated Ab was not detectable in the CSF nor in RIPA-soluble tissue fraction but in SDS-soluble fractions of AD brains. In keeping with this, nitrated Ab was immunohistochemically localized to the core of plaques of APP/PS1 mice and human AD brains, suggesting that it serves as a seeding structure. In addition, immunohistometrical plaque analysis of APP/PS1 mice at 5 and 9 months of age revealed that the 3NTyr 10 -Ab positive cores of amyloid plaques do not grow over this period of time, whereas total plaque size increased. This suggests that nitration of Ab defines the number of amyloid plaques, but not their size once formed. Supporting this assumption, injection of nitrated Ab resulted in seeding of microplaques within a short period of time. Hence, this posttranslational Ab modification may explain why injection of synthetic Ab into AD mouse models fails as a seeding agent in AD mouse models (Meyer-Luehmann et al., 2006; Eisele et al., 2009) , in contrast to the use of brain homogenates from murine AD models or human AD brains, both of which supposedly contain nitrated Ab. Nevertheless, we neither can rule out other NO-induced mechanisms including synaptic failure and neuronal cell death (Nakamura and Lipton, 2009) contributing to the protective effect of NOS2 deletion.
The observation that expression of murine APP, lacking the tyrosine within the Ab domain, does not result in Ab deposition in mice (Jankowsky et al., 2007) but in rodents endogenously possessing this tyrosine (Inestrosa et al., 2005) , suggests a critical role for this amino acid in b-amyloidosis. Nevertheless, this has to be confirmed experimentally.
It has been known that fibrillar Ab is able to activate microglia (Meda et al., 1995) , resulting in the induction of NOS2 expression (Combs et al., 2001; Tran et al., 2001; Ishii et al., 2000) . This in turn may generate a self-perpetuating cycle of Ab aggregation and NO production that contributes to the chronicity and progression of AD.
One might argue that the nitration yields under inflammatory conditions are relatively low, resulting in the modification of only 0.01%-0.05% of all tyrosine residues (Radi, 2004) . However, in a gain-of-function scenario, nitrated Ab may focally accumulate over a life time, thereby facilitating the rate-limiting nucleation step for the initiation of plaque deposition. In support of this, an 8-fold increase of nitrated proteins has been observed in AD (Smith et al., 1997) . Further, assessing the overall amount of nitrated proteins in the hippocampus of MCI patients, an equivalent to the nitration of purified BSA achieved with 27 mM peroxynitrite was estimated (Butterfield et al., 2007) , exposing the drastic consequences from chronic exposure to nitric oxide radicals.
Nitration induced oligomerization has also been reported for other disease-related proteins. Recently, the effects of peroxynitrite on oligomerization of a-synuclein by formation of covalent dityrosine cross-links has been demonstrated . In addition, a widespread accumulation of nitrated a-synuclein has found in several neurodegenerative diseases associated with Lewy bodies . Furthermore, the presence of nitrated tau in AD brains and its peroxynitriteinduced oligomerization has been observed (Horiguchi et al., 2003) .
Together, our data identify a posttranslational modification of Ab and characterize its functional implication that provides evidence for a link between the amyloid and neuroinflammatory component of AD. We think that 3NTyr 10 -Ab may be a promising target for a course modifying therapy of AD. The application of specific inhibitors of NOS2 may therefore open a new therapeutic avenue in AD.
EXPERIMENTAL PROCEDURES
Animals APP/PS1 transgenic animals (#005864, The Jackson Laboratory) (Jankowsky et al., 2001 ) and NOS2-deficient animals (# 002609, The Jackson Laboratory) (Laubach et al., 1995) were both of the BC57/Bl6 genetic background. L-NIL was given orally in the water either from 2-3-months or 7-12 months of age (8 mg/kg body weight). L-NIL was replaced daily. Mice were housed under standard conditions at 22 C and a 12 hr light-dark cycle with free access to food and water. Animal care and handling was performed according to the declaration of Helsinki and approved by the local ethical committees.
Radial Arm Maze
Learning and memory testing was conducted in an eight arm maze as previously described (Olton, 1987) . Briefly, each arm of the maze was 60 cm long and 6 cm wide and extended from an octagonal central platform 10 cm in diameter. One centimeter deep food cups were placed 2 cm from the end of each arm. Several visual cues were put outside of the maze, and the room was lit dimly. Mice were trained for 3 days. During each training session, the mouse was placed on the center platform and allowed to move freely in the maze to obtain food pellets, which were presented in all eight arms, for 10 min. Starting day 4, the mice were tested once per day for a total of 14 days. During the test sessions, four randomly selected arms were baited with one pellet of food each; the baited arms were kept unchanged throughout the experiment. The mouse was allowed to move until it collected the four pellets or until 10 min passed, whichever occurred first. Parameters evaluated were reentry into baited arms that had been visited during the session (working memory error) and entries into unbaited arms (reference memory error).The task was considered learned when the working memory error was zero and the average reference memory error was one or less than one in three successive sessions.
Brain Protein Extraction
Snap-frozen brain hemispheres were extracted as previously described (Jardanhazi-Kurutz et al., 2010) .
Tissue Preparation
After completion of the behavioral testing, mice were anesthetized using isoflurane and transcardially perfused with 15 ml phosphate-buffered saline. The brains were removed from the skull. One hemisphere was frozen immediately for biochemical analysis and the other was frozen in a mixture of dry ice and isopentane for histology.
Protein Blotting
Samples were separated by 4%-12% NuPAGE (Invitrogen) using MES or MOPS buffer and transferred to nitrocellulose membranes. APP and Ab were detected using antibody 6E10 (Covance) and the C-terminal APP antibody 140 (CT15) (Wahle et al., 2006) , IDE using antibody PC730 (Calbiochem), neprilysin using antibody 56C6 (Santa Cruz), presenilin using antibody PS1-NT (Calbiochem), and tubulin using antibody E7 (Developmental Studies Hybridoma Bank). For dot blot analysis, 10 ml samples containing 25 mM peptide were mixed with 200 ml PBS and transferred to nitrocellulose membranes. Immunoreactivity was detected by enhanced chemiluminescence reaction (Millipore; luminescence intensities were analyzed using Chemidoc XRS documentation system [Bio-Rad] ).
ELISA
Quantitative determination of Ab was performed using the human amyloid Ab 1-40 and Ab 1-42 ELISA kits (The Genetics Company) according to the manufacturer's protocol. Human samples were analyzed using an electrochemoluminescence ELISA for Ab 1-38 , Ab 1-40 , and Ab 1-42 (Mesoscale). pTau181 was determined using the INNOTEST PHOSPHO-TAU(181P) ELISA (Innogenetics). For 3NTyr 10 -Ab, 96-well plates were coated with 50 ml 20 mg/ml 3NTyr 10 -Ab antiserum in PBS 4 hr at 20 C. Plates were blocked with 3% BSA in TBS.
Ten microliters of 2% SDS fractions from mouse brain were diluted with 50 ml 2% Tx-100, 25 mM Tris-HCl (pH 7.5), and 150 mM NaCl. Fifty microliters samples were incubated for 18 hr at 4 C, washed with TBST, and incubated with 6E10 diluted 1:10,000 in TBST for 2 hr. Wells were washed, and 50 ml HRP-goat anti-mouse antibody diluted 1:10,000 with TBST was added for 2 hr. After washing, 50 ml TMB ultra substrate (Thermo) was added and the reaction was stopped using 2M sulfuric acid. Absorption was determined at 450 nm using an infinite 200 plate reader (Tecan).
Histology
Serial sagittal cryosections (20 mm) were fixed in 4% paraformaldehyde, and immunostaining was performed using antiserum 3NTyr (Wahle et al., 2006) , and antibody IC3 (Kato et al., 2000) against dityrosine (1:100). Thioflavin S staining was performed on paraformaldehyde-fixed cryosections. Slices were rinsed in water, incubated in 0.01% thioflavin S in 50% ethanol, and differentiated in 50% ethanol. Sections were analyzed using a BX61 microscope equipped with a disk scanning unit to achieve confocality (Olympus). Image stacks were deconvoluted using Cell^P (Olympus). Quantitative assessment of plaque areas was done using ImageJ (NIH; Bethesda, MD) software.
Immunoprecipitation Brains were extracted as described before with the following changes: homogenates were centrifuged at 100,000 3 g for 20 min to generate the PBS fraction. The pellet of the SDS fraction was extracted with 1,1,1-6,6,6-hexafluoroisopropanol (HFIP), dried in a speed vac and resuspended in 2% SDS. For immunoprecipitation, samples were diluted in 5 vol. of RIPA buffer and incubated for 18 hr at 4 C with protein G agarose and 3 ml 3-NTyr 10 -Ab.
Precipitates were washed twice with RIPA and once with PBS and immunoblotted using antibody 6E10.
Ab Aggregation Assay Ab 1-42 , Ab 1-42 Y10F (Peptide Specialty Laboratories) were solubilized as previously described (Teplow, 2006) . For nitration, samples were incubated with 0.25-0.5 mM peroxynitrite in water while vortexing. Aggregation was started by diluting samples to 25 mM using 50 mM Tris-HCl (pH 7). Samples were separated by 4%-12% NuPAGE, and aggregates were detected using antibody 6E10 (Signet) and 3-NTyr 10 -Ab. Aggregation was expressed as a ratio between the signal above 30 kDa and the Ab monomer, normalized to the 0 time point of Ab 1-42 . Thioflavin T fluorescence assays were performed as described previously (LeVine, 1999) . Fluorescence was read at 446 nm (excitation) and 482 nm (emission) using a fluorescence spectrophotometer (Varian). For determination of the solubility of dityrosine linked Ab, samples were aged for 5 hr and centrifuged at 10, 000 3 g for 1 hr. Pellets were resuspended in 50 mM Tris (pH 7) and analyzed by dot blot.
The antiserum recognizing the 3-NTyr 10-Ab was generated by rabbit immunization using the synthetically nitrated peptide FRHDSG(3NT-Y)EVHHQ (Eurogentech). The resulting serum was first immunopurified against the nitrated peptide and subsequently antibodies against the unmodified peptide were removed by immunochromatography against the peptide FRHDSGYEVHHQ.
Human Samples Human brain samples were from the parietal cortex of 5 age control and 8 diagnosed AD patients (Braak staging V-VI, CERAD B-C). The post mortem interval (PMI) was comparable among groups ranging from 4-48 hr. Samples were extracted as the mouse brains described above with the exception that instead of RIPA buffer 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Tx-100 was used. CSF samples were from 10 control, 10 mild cognitive impaired, and 10 diagnosed AD patients.
Intracerebral Injections
Two and one-half-month-old APP/PS1 mice (n = 3) were anesthetized with ketamine (30 mg/kg) and xylazine (4 mg/kg). Two and one-half microliters of 0.25 mg/ml Ab solutions were injected intracortically into the right hemisphere anteroposterior -2.5, lateral 2.0 at 1.0 mm (cortex), and in addition at 1.5 mm (hippocampus) depth relative to the bregma at a rate of 1 ml/min. Control solutions were injected into the left hemisphere, accordingly. Mice were sacrificed 8 weeks later. Cryosections in the proximity of the injection channel were stained using antibodies IC16, 3NTyr10-Ab, and anti-Iba1 (1:400, Wako).
Slice Preparation
Acute hippocampal transversal slices were prepared from 40-to 60-day-old wild-type C57BL/6 mice (P40-60) according to standard procedures. In brief, mice were anesthetized and decapitated, the brain was quickly transferred into ice-cold carbogenated (95% O 2 , 5% CO 2 ) artificial cerebrospinal fluid (ACSF) which contained 125.0 mM NaCl, 2.0 mM KCl, 1.25 mM NaH2PO4, 2.0 mM MgCl2, 26.0 mM NaHCO3, 2.0 mM CaCl2, 25.0 mM glucose. Hippocampi were dissected and cut into 400 mm thick transversal slices with a vibratome (Leica, VT1200S). Slices were maintained in carbogenated ACSF at room temperature for at least 1.5 hr before recording. Recordings were performed in a submerged recording chamber at 32 C.
Electrophysiology
To study the effect of acute Ab application on LTP three different samples were used: (1) untreated Ab 1-42 , (2) nitrated Ab 1-42 with peroxynitrite (500 mM), (3) a control sample where all nitration steps were performed without adding Ab 1-42 (control). Ab 1-42 was prepared as previously described (Teplow, 2006) . Nitration was carried out by adding water diluted peroxynitrite to Ab 1-42 or control sample solution while vortexing. The solutions were freshly
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Nitration of Amyloid b in Alzheimer's Disease prepared in carbonated ACSF from frozen aliquots with a final concentration of 500 nM. Silicon tubing was used and BSA (0.1 mg/ml) was added to the peptide containing as well as to the control solutions (Chen et al., 1999) . Tubings and beakers were washed with ACSF containing BSA to prevent sticking of the peptide. A closed-loop perfusion system with a total volume of 30 ml perfusion medium was used. The perfusion rate in the recording chamber was constantly kept at 1.0 ml/min. After placing the slices in the submerged recording chamber field excitatory postsynaptic potentials (fEPSPs) were recorded in stratum radiatum of CA1 region with a borosilicate glass micropipette (resistance 3-15 MU) filled with 3 M NaCl at a depth of 90-120 mm. Monopolar tungsten electrodes were used for stimulating the Schaffer collaterals at a frequency of 0.1 Hz. Stimulation was set to elicit a fEPSP with a slope of 40% of maximum for LTP recordings and 60% for LTD recordings. After 20 min prebaseline stimulation, the three different samples were washed into the chamber and the baseline was recorded for another 40 min. LTP was induced by applying theta-burst stimulation (TBS). One burst consists of four pulses at 100 Hz, repeated 10 times in an 200 ms interval. Three such bursts were used to induce LTP at 0.1 Hz.
To study the effect of NOS2 deficiency on LTP, brains were dissected and sagittally sliced in 400 mm sections using a vibratome (Camden Instruments, Integraslice 7550 PSDS). The recording of the field excitatory postsynaptic potential (fEPSP) was initiated after 15 min of basal recording. Basal synaptic transmission (BST) was assessed by plotting the current (mA) against the peak amplitudes of fEPSP to generate input-output relations. Paired-pulse facilitation (PPF) were recorded by applying interstimulus intervals of 30, 50, 75, and 100 ms. For long-term potentiation (LTP) experiments a 15 min baseline were recorded with a interpulse interval of 1 min at an intensity that evoked a response approximately 30% of maximum fEPSP. The LTP was induced by a theta burst consisting of 4 trains of 10 pulses at 100 Hz separated by 200 ms.
Data Analysis
Data were collected, stored and analyzed with LABVIEW software (National Instruments, Austin, TX). The initial slope of fEPSPs elicited by stimulation of the Schaffer collaterals was measured over time, normalized to baseline, which was the mean response of the 40 min before TBS application and plotted as average ± SEM. Parameters leading to an exclusion of single experiments were (1) an unstable baseline (variability more than ± 10%) or (2) a large population spike after TBS application producing an artificially large LTP.
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